Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468000 · ClinicalTrials.gov registry record · Phase 2
Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia
A Phase 2 study of Peripheral Arterial Disease, sponsored by Vericel Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 20
- Study locations
NCT00468000: Completed Phase 2 study of Peripheral Arterial Disease, sponsored by Vericel Corporation.
NCT00468000 is a Phase 2 study of Peripheral Arterial Disease that has completed, run by Vericel Corporation. The registered enrollment target is 86 participants, below the 4,205-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00468000, a Phase 2 study of Peripheral Arterial Disease, has completed, sponsored by Vericel Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the safety and efficacy of autologous Vascular Repair Cells (VRC) for patients with peripheral arterial disease as a treatment for critical limb ischemia. The double-blind study is expected to enroll 150 patients, randomized into two patient groups. The treatment group will receive intramuscular (IM) injections of the VRCs into the affected limb; the control group will receive intramuscular injections with an electrolyte solution (without cells). Both groups will receive the standard of care appropriate for their medical condition.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Ixmyelocel-T
Study Locations (20)
Michigan
- VA Ann Arbor Healthcare System - Ann Arbor
- St. Joseph Mercy Hospital - Ann Arbor
- Michigan Vascular Research Center - Flint
Florida
- Malcolm Randall Veterans Administration Medical Center, part of the North Florida/South Georgia Veterans Health System - Gainesville
- University of Miami/Miller School of Medicine - Miami
Illinois
- Loyola University Stritch School of Medicine - Maywood
- Southern Illinois University School of Medicine - Springfield
Texas
- Peripheral Vascular Associates - San Antonio
- Scott and White Hospital - Temple
Alabama
- Cardiology, P.C. - Birmingham
Arizona
- Arizona Heart Institute - Phoenix
California
- University of California, San Francisco - San Francisco
Indiana
- The Care Group, LLC - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
What the finished NCT00468000 record still lists
NCT00468000 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 4,205-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00468000 names 20 study sites across 15 states, led by Michigan, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00468000 about?
NCT00468000 is a clinical study titled "Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia". This study is designed to evaluate the safety and efficacy of autologous Vascular Repair Cells (VRC) for patients with peripheral arterial disease as a treatment for critical limb ischemia. The double-blind study is expected to enroll 150 patients, randomized into two patient groups. The treatment ...
What is the current status of trial NCT00468000?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2007-04. Estimated completion is 2011-03.
What conditions does trial NCT00468000 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT00468000?
The interventions under investigation include: Placebo (BIOLOGICAL), Ixmyelocel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT00468000?
This trial is sponsored by Vericel Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00468000 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00468000's enrollment target sits among peer trials
86 41st of 79 higher than 39 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fisetin to Reduce Senescence and Mobility Impairment in PAD
RECRUITING · Phase 2
-
Passive Stretching in Peripheral Arterial Disease Patients
RECRUITING · Phase 2
-
Edoxaban in Peripheral Arterial Disease
COMPLETED · Phase 2
-
Nitrites, Exercise, and Peripheral Arterial Disease
COMPLETED · Phase 2
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia